Sign up for the QMED & MD+DI Daily newsletter.
Senseonics Blossoms in Favorable CGM Environment
The Germantown, MD-based company beat revenue consensus and maintained guidance.
May 13, 2022
1 Min Read
Image courtesy of Dennis Diatel / Alamy Stock Photo
Companies that are primarily continuous glucose management seem to be having a significant level of success in 2022. The latest CGM specialist to have success is Senseonics.
The Germantown, MD-based company reported revenue of $2.5 million above consensus of $2.2 million. The company also maintained its revenue guidance of $14 million to $18 million.
Some of the reasons for the success with revenue was because of the launch of the 180-day Eversense CGM in April.
Marie Thibault, an analyst with BTIG and former managing editor of MD+DI, said Senseonics was off to a “solid start” for the year. Thibault said there could be some significant news about the 365-day version of the device on the horizon.
“First data from the 365-day pilot trial will be presented at the American Diabetes Association (ADA) conference next month,” Thibault wrote in research notes. “The company anticipates the first patients in the pivotal trial will be inserted with the longer duration sensor in 4Q22.”
About the Author(s)
You May Also Like
Sustainable Manufacturing Expo Hits North AmericaFeb 22, 2024|4 Min Read
Medtronic Doubles Down on Sustainability EffortsFeb 22, 2024|1 Min Read
Top Medical Device M&AFeb 21, 2024|1 Min Read
FDA Urges Independent Verification of Third-Party Testing DataFeb 21, 2024|2 Min Read